AVITA Medical (RCEL) Status Update summary

Strategic transformation and product innovation

• Undergoing significant strategic transformation focused on patients, physicians, employees, and shareholders, with emphasis on the RECELL platform and portfolio expansion for market leadership.

• Expanding product portfolio to address burns, surgical, traumatic, and chronic wounds, including RECELL GO, RECELL GO mini, PermeaDerm, and COHEALYX.

• RECELL GO launched to improve workflow and patient outcomes, with 100% account conversion targeted by end of Q3 2024.

• International expansion underway, targeting Europe, Australia, and Japan through third-party distributors, with CE mark approval for RECELL GO expected soon.

• Building a comprehensive wound care continuum by integrating dermal matrices and advanced dressings to enhance healing and outcomes.

Product and commercialization updates

• RECELL GO mini anticipated FDA approval by December 27, 2024, targeting smaller wounds.

• Exclusive agreement with Regenity Biosciences for a collagen-based dermal matrix, with 510(k) clearance expected in Q4 2024 and U.S. commercialization to follow.

• Portfolio expansion includes PermeaDerm biosynthetic dressing and COHEALYX dermal matrix, with COHEALYX expected to launch in Q4 following regulatory clearance.

• Pipeline of new accounts for full-thickness skin defect indication doubled, with 89 in Q3 pipeline and anticipated 50–70 new account conversions.

• Expanding into trauma centers and advancing through VAC approval, targeting at least 45 new accounts per quarter.

Financial performance and guidance

• Q2 2024 revenue reached $15.1 million, up 29% year-over-year, with gross margin at 86.2%.

• Q3 2024 revenue guidance set at $19–20 million, representing 40–48% year-over-year growth.

• Full-year 2024 revenue guidance reduced to $68–70 million, still reflecting over 37% growth over 2023.

• Cash and cash equivalents stood at $54.1 million as of June 30, 2024, supporting growth and profitability targets.

• Profitability and cash flow breakeven targeted for Q3 2025, supported by high gross margins and stable operating expenses.